| Ytd | 109.75% | |
| 1y | 1.85% |
| Open | 5.19 | Prev Close | 5.20 | Low | 4.86 | High | 5.42 | Mkt Cap | 476.65M |
| Vol | 2.43M | Avg Vol | 1.82M | EPS | -0.81 | P/E | N/A | Forward P/E | -3.42 |
| Beta | 1.19 | Short Ratio | 3.16 | Inst. Own | 64.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-12 | 50-d Avg | 3.81 | 200-d Avg | 5.11 | 1yr Est | 13.00 |
RZLT News
Presentations included analyses of natural history and adverse outcomes in congenital hyperinsulinis
Guggenheim analyst Debjit Chattopadhyay maintains Rezolute (NASDAQ:RZLT) with a Buy and raises th
Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage ultra-rare
Maxim Group analyst Jason McCarthy maintains Rezolute (NASDAQ:RZLT) with a Buy and raises the pri
Dow falls 296 points. Navitas Semi rises on partnership with Nvidia. Other gainers: ABVX, MMED, KELY
Citizens analyst Jason N. Butler upgrades Rezolute (NASDAQ:RZLT) from Market Perform to Market Ou
Wedbush analyst Yun Zhong maintains Rezolute (NASDAQ:RZLT) with a Outperform and raises the price
U.S. stock futures surged on Wed. as Nasdaq futures rose over 7%, driven by AI. Marvell's stock
Rezolute says 6 of 8 patients met the primary endpoint in its Phase 3 upLIFT study of ersodetug for
HC Wainwright & Co. analyst Douglas Tsao reiterates Rezolute (NASDAQ:RZLT) with a Buy and mai
Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage ultra-rare